A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg

Inclusion Criteria: * Adult male or female same or older than age of 40 * Severity of acute exacerbation of Chronic obstructive pulmonary disease(COPD) must suit oral administration treatment * Diagnosed as COPD before receiving written informed consent and outcome measure of spirometry testing confirmed as \[Ratio of Forced Expiratory Volume in 1 second(FEV1) to Forced Vital Capacity(FVC)\](FEV1/FVC) \< 0.7 * Subject showing following signs and symptoms: (i)Purulent Sputum or Sputum level is increased (ii)Difficulty in breathing is increased * Female subjects who might be pregnant must do pregnancy test and results should be negative before randomization is done. She must receive written informed consent form (NOTE: Subject who has used single hormone contraception for pregnancy control or has not been more than 1 year after Tubule ligation and menopause are excluded from the study) * Subject who can agree and sign written informed consent form approved by Institutional Review Board(IRB) before participating in study and follow study requirements Exclusion Criteria: * Subject who administered excess daily dose of antimicrobial/antibiotics in past 72 hours before receiving written consent * Diagnosed to have pneumonia by taking chest X-ray in past 48 hours before receiving written consent * Diagnosed to have infectious diseases or such diseases results in complications before receiving written consent (NOTE: Septic shock, Bronchiectasis, Lung abscess, Pneumonia, Active tuberculosis, Pulmonary malignancy, Cystic fibrosis, Empyema, Asthma) * Have kidney or liver diseases who correspond following criteria: (i) Creatinine Clearance(CCr) \< 50 mL/min (ii) Blood Urea Nitrogen(BUN) ≥ 30 mg/dl (iii) Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) \> 3 x Upper Limit Normal(ULN) (iv) Total bilirubin \> 2 x ULN (v) Alkaline Phosphatase(ALP) \> 2 x ULN. * Organic gastrointestinal disorder having abnormal absorption problem condition in past 6 months before receiving written consent (NOTE: Active Crohn's disease, active ulcerative colitis) * Diagnosed to have neutropenia where absolute neutrophil count is \< 1,000cells/mm3 (NOTE: Even though subject neutrophil count is \< 1,000cells/mm3, if it is acute infection, subject maybe possible to participate) * Chronic Hepatitis B carrier * Have proof that subject is Hepatitis C carrier or have Hepatitis C antibody * Immunodeficiency diseases such as HIV positive, AIDS, Bone marrow transplant or leukemia * Have medical history of hypersensitive reaction to antibiotics of fluoroquinolones * Have medical history of seizure or administration of anti-seizure drug in past 1 year before receiving written consent (NOTE: Epilepsy, Convulsions, Myasthenia gravis) * Medical history of ventricular arrhythmia * Medical history of QTc prolongation or currently administering drug that delays QTc interval (NOTE: QTc prolongation means QTc interval \> 450 msec) * Complex infections or diseases that can effect study assessment or need long-term antibiotic treatment exceeding 7 days * Subject who has participated in Clinical trials or Bioequivalence test in past 30 days before receiving written consent * Clinically significant by observations considered as unsuitable based on medical judgement by investigators where current condition can effect quality of safety or data